Skip To Main Content

This website is intended exclusively for the healthcare professionals residing and/or working in Malaysia.

Acute coronary syndrome

P2Y12 inhibitors vs. NSAIDs : Latest Evidence for Optimal Antiplatelet Therapy

P2Y12 inhibitors vs. NSAIDs : Latest Evidence for Optimal Antiplatelet Therapy

Keep scrolling to explore ACS updates

Evidence-Based Antiplatelet Selection in ACS patients

Evidence-Based Antiplatelet Selection in ACS patients

Keep scrolling to explore ACS updates

Personalizing Antiplatelet Therapy in Complex PCI & High-Risk Coronary Interventions

Personalizing Antiplatelet Therapy in Complex PCI & High-Risk Coronary Interventions

Keep scrolling to explore ACS updates

Comprehensive Insights into ACS: From Platelet Reactivity to Treatment Adherence

Comprehensive Insights into ACS: From Platelet Reactivity to Treatment Adherence

Antiplatelet Therapy in ACS: Moving Beyond One-Size-Fits-All

Antiplatelet Therapy in ACS: Moving Beyond One-Size-Fits-All

Personalizing Antiplatelet Therapy: Insights for High-Risk PCI Patients

Personalizing Antiplatelet Therapy: Insights for High-Risk PCI Patients

Personalizing Cardiovascular Care in Asian Populations: Insights on Antiplatelet Safety & Lipid Risk

Personalizing Cardiovascular Care in Asian Populations: Insights on Antiplatelet Safety & Lipid Risk

Dual Therapy, FCAPs, and Antiplatelets: Recent Evidence You Should Know

Dual Therapy, FCAPs, and Antiplatelets: Recent Evidence You Should Know

Please log in or register to continue reading.